Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to -$1.1 million.

  • Adma Biologics' Free Cash Flow fell 10448.44% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.7 million, marking a year-over-year decrease of 4870.07%. This contributed to the annual value of $110.4 million for FY2024, which is 264127.58% up from last year.
  • Latest data reveals that Adma Biologics reported Free Cash Flow of -$1.1 million as of Q3 2025, which was down 10448.44% from $18.7 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Free Cash Flow ranged from a high of $47.5 million in Q4 2024 and a low of -$37.1 million during Q4 2021
  • In the last 5 years, Adma Biologics' Free Cash Flow had a median value of -$11.1 million in 2022 and averaged -$4.8 million.
  • In the last 5 years, Adma Biologics' Free Cash Flow skyrocketed by 72876.93% in 2024 and then tumbled by 43397.59% in 2025.
  • Adma Biologics' Free Cash Flow (Quarter) stood at -$37.1 million in 2021, then skyrocketed by 70.04% to -$11.1 million in 2022, then soared by 247.38% to $16.4 million in 2023, then surged by 189.38% to $47.5 million in 2024, then crashed by 102.27% to -$1.1 million in 2025.
  • Its Free Cash Flow was -$1.1 million in Q3 2025, compared to $18.7 million in Q2 2025 and -$24.4 million in Q1 2025.